← ALL REGULATORY INTELLIGENCEKNOWLEDGE / REGULATORY DEVELOPMENTS
DRAP5 November 2026 — official sourceRapid Alert I/S/11-05-51

DRAP names three unregistered tablet products and specific batches in Rapid Alert 51

Unregistered products — rapid alertRapid Alert I/S/11-05-51

Rapid Alert I/S/11-05-51 identifies Flecainide Acetate 50 mg, Modafinil 200 mg and Mysoline 250 mg tablet samples as unregistered, with the affected batch numbers specified.

Rapid Alert I/S/11-05-51 identifies Flecainide Acetate 50 mg, Modafinil 200 mg and Mysoline 250 mg tablet samples as unregistered, with the affected batch numbers specified.

01 / REGULATORY ANALYSIS

The listed products and batches

The Central Drugs Laboratory, Karachi, reported the following products unregistered: Flecainide Acetate 50 mg tablet, batch FDAG020; Modafinil 200 mg tablet, batch MDSB25008A; and Mysoline 250 mg tablet, batch 4626. DRAP published the findings on 5 November 2026 as Rapid Alert I/S/11-05-51.

The published notice also identifies relevant manufacturer names. Traders and healthcare facilities should match complete product, batch and packaging details before concluding that a particular stock item is affected.

02 / REGULATORY ANALYSIS

Meaning of the classification

DRAP's finding is that the listed samples are unregistered. This is distinct from a laboratory finding that every batch of the same active ingredient is chemically substandard. The notice warns of possible safety and quality consequences and calls for surveillance of the supply chain.

No claim is made here that all competing or properly registered preparations containing these ingredients have been recalled.

03 / REGULATORY ANALYSIS

Action for pharmacies and distributors

Search stock and invoices for the identified products and batches, confirm registration documentation and the source of supply, preserve an audit trail and refer any disputed identity or authenticity to the proper drug-control authority. Do not supply affected stock contrary to DRAP's advice.

Healthcare professionals should report suspected adverse events or product defects. Patients should consult their treating clinician on any treatment alternatives rather than rely on a non-clinical product summary.

04 / REGULATORY ANALYSIS

Scope of legal risk

Recordkeeping, authorised procurement and batch traceability are the immediate compliance priorities. Any further enforcement finding must be established from its own authoritative record.

Related reading

For other notices, decisions and regulatory developments, see the Regulatory Intelligence archive. This report does not treat a proposed measure or operational notice as enacted law.

OFFICIAL SOURCERapid Alert I/S/11-05-51

Drug Regulatory Authority of Pakistan — 5 November 2026

READ SOURCE ↗